Researchers have demonstrated that bioavailability tests in patients to reveal anti-drug antibody levels could aid personalised medicine.
List view / Grid view
Rheumatoid arthritis (RA)
Filter the results
A study of baricitinib in combination with remdesivir has met its primary endpoint in COVID-19 patients, by reducing time to recovery in comparison with only remdesivir.
Dapivirine Vaginal Ring (dapivirine) and Blenrep (belantamab mafodotin) have been recommended for approval by the EMA's CHMP, along with nine other medicines.
Companies leading trial announce Kevzara failed to meet primary and secondary endpoints in critically ill COVID-19 patients, so the trial has been halted.
A Phase III trial has been launched to study whether baricitinib, an oral JAK1/JAK2 inhibitor, is effective at combatting COVID-19 in hospitalised patients.
A double-blind clinical trial has begun in the US to study hydroxychloroquine and azithromycin treatment in patients with COVID-19.
Scientists have developed a protocol for encapsulating antibodies in an ultrasound-sensitive drug carrier for targeted drug delivery.
The enterprise announced its drug OLUMIANT® (baricitinib) and an investigational antibody will enter clinical trials in US COVID-19 patients later this month.
The EMA’s human medicines committee (CHMP) recommended fifteen medicines for various approvals at its January 2020 meeting; with ten drugs receiving marketing authorisation recommendations and five receiving positive opinions for specific treatments.
As the demand for safety-syringes increases, the market for pre-filled safety-engineered devices will increase. This article outlines the main drivers behind this growth.
RediTrex, a new line of methotrexate products, has been approved by the FDA for the treatment of patients with rheumatoid arthritis.
Remsima SC™ is the world’s first subcutaneous formulation of infliximab and has been approved in the EU for the treatment of people with rheumatoid arthritis.
New data shows the non-inferiority of efficacy for the subcutaneous (SC) formulation of CT-P13 to the intravenous (IV) formulation of CT-P13 in people with rheumatoid arthritis.